60
Participants
Start Date
January 31, 2009
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2009
TAK-875
"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
Lead Sponsor
Takeda
INDUSTRY